New antibiotic zavicefta under Real-World watch in korea
NCT ID NCT05733104
First seen Sep 30, 2025 · Last updated May 14, 2026 · Updated 26 times
Summary
This study tracks the safety and effectiveness of Zavicefta, an antibiotic already approved in Korea, in 600 patients with serious abdominal, urinary tract, or hospital-acquired lung infections. Researchers will record any side effects and how well the drug works. The goal is to confirm real-world performance, not to test a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COMPLICATED INTRA-ABDOMINAL INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Pfizer
RECRUITINGSeoul, Gangnam-gu, 06273, South Korea
Conditions
Explore the condition pages connected to this study.